Why Kymera Therapeutics (KYMR) Shares Are Surging Today - Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics Inc KYMR announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.
KT-474 demonstrated robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile.
KT-474 showed IRAK4 knockdown in blood and skin comparable to MAD3, with maximum degradation exceeding 90%. Target degradation was similar across HS and AD patients in blood and skin.
In ex vivo cytokine stimulation assays, KT-474 demonstrated broad and deep inhibition of multiple disease-relevant cytokines, including inhibition of up to 84% in HS and up to 98% in AD.
KT-474 also reduced several circulating cytokines and acute phase reactants in vivo.
Sanofi SNY, collaborating with Kymera on developing KT-474 (SAR444656) outside of the oncology and immune-oncology fields, has notified Kymera of its commitment to advance KT-474 into Phase 2 clinical studies.
The initial Phase 2 trial of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
Price Action: KYMR shares are up 22.2% at $31.57 on the last check Wednesday.
Photo Via Company

Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial